- Published on
Emergency and Acute Medicine – Lymphogranuloma Venereum
Basics description
Lymphogranuloma venereum (LGV) is a sexually transmitted infection characterized by an initial painless genital lesion followed by regional lymphatic spread. The disease progresses through primary, secondary, and tertiary stages and is responsive to appropriate antibacterial therapy in early phases. LGV is endemic in Southeast Asia, Latin America, parts of Africa, and the Caribbean, with increasing incidence among men who have sex with men. It is also known as struma, tropical bubo, or Nicolas–Favre–Durand disease.
Etiology
LGV is caused by Chlamydia trachomatis serotypes L1, L2, and L3.
Diagnosis signs and symptoms
The primary stage occurs after an incubation period of 3–30 days and presents as a painless papule, pustule, vesicle, or ulcer in the anogenital region. These lesions are transient, often last only a few days, and are frequently unnoticed. The secondary stage develops 1–3 weeks later with systemic symptoms such as fever, malaise, and myalgias, along with tender inguinal lymphadenopathy that may be unilateral or bilateral. Large, fluctuant lymph nodes (buboes) can ulcerate and drain purulent material. Proctitis is common in anal-receptive patients and may cause rectal bleeding, tenesmus, and constipation. The tertiary stage occurs in untreated disease and results in chronic inflammatory changes including proctocolitis, strictures, fistulae, and elephantiasis of the genitalia or lower extremities, mimicking inflammatory bowel disease.
Physical examination
Findings in the primary stage include a painless anogenital lesion. During the secondary stage, tender inguinal or femoral lymphadenopathy is typical, with buboes forming in up to two-thirds of cases. The “groove sign,” caused by lymph node enlargement above and below the inguinal ligament, may be seen. Anal-receptive patients may demonstrate signs of hemorrhagic proctocolitis. Advanced tertiary disease shows chronic inflammatory damage with strictures, fistulae, and elephantiasis.
Diagnosis tests and interpretation
Routine chlamydia nucleic acid amplification tests do not differentiate LGV strains. Diagnosis is based on clinical suspicion, epidemiologic context, and serologic testing. Complement fixation titers greater than 1:64 support the diagnosis. False-positive VDRL tests may occur. Bubo aspiration is specific but rarely practical and is not routinely required.
Differential diagnosis
Conditions to consider include genital herpes, syphilis, chancroid, and granuloma inguinale. Compared with LGV, syphilis typically causes nontender lymphadenopathy with a longer incubation period, while chancroid presents with painful ulcers and granuloma inguinale causes painless, friable lesions that bleed easily.
Treatment
No prehospital or emergency stabilization is typically required. Large, fluctuant buboes may require aspiration or drainage to reduce pain and scarring. First-line therapy is doxycycline 100 mg orally twice daily for 21 days. Alternative regimens include azithromycin 1 g orally weekly for 3 weeks or erythromycin 500 mg orally four times daily for 3 weeks. In pregnancy or during lactation, erythromycin is the recommended treatment.
Disposition and follow-up
Hospitalization is rarely necessary and is reserved for patients with severe systemic illness or complications. Most immunocompetent patients without systemic involvement can be discharged with outpatient management. Sexual partners within the previous 60 days should be tested and treated with appropriate antichlamydial therapy. Follow-up is essential to confirm cure, particularly in cases of rectal involvement, which may require retreatment.
Pearls and pitfalls
LGV should be suspected in at-risk populations, particularly men who have sex with men presenting with inguinal lymphadenopathy or proctitis. Early recognition and treatment are critical to prevent progression to tertiary disease, which may cause irreversible tissue damage and is less responsive to antibiotics alone.
Basics description
Lymphogranuloma venereum (LGV) is a sexually transmitted infection characterized by an initial painless genital lesion followed by regional lymphatic spread. The disease progresses through primary, secondary, and tertiary stages and is responsive to appropriate antibacterial therapy in early phases. LGV is endemic in Southeast Asia, Latin America, parts of Africa, and the Caribbean, with increasing incidence among men who have sex with men. It is also known as struma, tropical bubo, or Nicolas–Favre–Durand disease.
Etiology
LGV is caused by Chlamydia trachomatis serotypes L1, L2, and L3.
Diagnosis signs and symptoms
The primary stage occurs after an incubation period of 3–30 days and presents as a painless papule, pustule, vesicle, or ulcer in the anogenital region. These lesions are transient, often last only a few days, and are frequently unnoticed. The secondary stage develops 1–3 weeks later with systemic symptoms such as fever, malaise, and myalgias, along with tender inguinal lymphadenopathy that may be unilateral or bilateral. Large, fluctuant lymph nodes (buboes) can ulcerate and drain purulent material. Proctitis is common in anal-receptive patients and may cause rectal bleeding, tenesmus, and constipation. The tertiary stage occurs in untreated disease and results in chronic inflammatory changes including proctocolitis, strictures, fistulae, and elephantiasis of the genitalia or lower extremities, mimicking inflammatory bowel disease.
Physical examination
Findings in the primary stage include a painless anogenital lesion. During the secondary stage, tender inguinal or femoral lymphadenopathy is typical, with buboes forming in up to two-thirds of cases. The “groove sign,” caused by lymph node enlargement above and below the inguinal ligament, may be seen. Anal-receptive patients may demonstrate signs of hemorrhagic proctocolitis. Advanced tertiary disease shows chronic inflammatory damage with strictures, fistulae, and elephantiasis.
Diagnosis tests and interpretation
Routine chlamydia nucleic acid amplification tests do not differentiate LGV strains. Diagnosis is based on clinical suspicion, epidemiologic context, and serologic testing. Complement fixation titers greater than 1:64 support the diagnosis. False-positive VDRL tests may occur. Bubo aspiration is specific but rarely practical and is not routinely required.
Differential diagnosis
Conditions to consider include genital herpes, syphilis, chancroid, and granuloma inguinale. Compared with LGV, syphilis typically causes nontender lymphadenopathy with a longer incubation period, while chancroid presents with painful ulcers and granuloma inguinale causes painless, friable lesions that bleed easily.
Treatment
No prehospital or emergency stabilization is typically required. Large, fluctuant buboes may require aspiration or drainage to reduce pain and scarring. First-line therapy is doxycycline 100 mg orally twice daily for 21 days. Alternative regimens include azithromycin 1 g orally weekly for 3 weeks or erythromycin 500 mg orally four times daily for 3 weeks. In pregnancy or during lactation, erythromycin is the recommended treatment.
Disposition and follow-up
Hospitalization is rarely necessary and is reserved for patients with severe systemic illness or complications. Most immunocompetent patients without systemic involvement can be discharged with outpatient management. Sexual partners within the previous 60 days should be tested and treated with appropriate antichlamydial therapy. Follow-up is essential to confirm cure, particularly in cases of rectal involvement, which may require retreatment.
Pearls and pitfalls
LGV should be suspected in at-risk populations, particularly men who have sex with men presenting with inguinal lymphadenopathy or proctitis. Early recognition and treatment are critical to prevent progression to tertiary disease, which may cause irreversible tissue damage and is less responsive to antibiotics alone.
0 Comments
